<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04497792</url>
  </required_header>
  <id_info>
    <org_study_id>16_001</org_study_id>
    <nct_id>NCT04497792</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions</brief_title>
  <acronym>SAFARY</acronym>
  <official_title>A Long-term, Randomized Study to Evaluate the Effects of Empagliflozin in Combination With Standard Hypoglycemic Therapy on Early and Long-term Results of Planned Percutaneous Coronary Interventions in Patients With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Institute for Complex Problems of Cardiovascular Diseases, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Research Institute for Complex Problems of Cardiovascular Diseases, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To study the effectiveness and safety of empagliflozin as a preoperative preparation&#xD;
      tool, as well as to improve the long-term prognosis of planned percutaneous coronary&#xD;
      interventions in patients with type 2 diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with type 2 diabetes will be randomized into 2 groups using the envelope method. One&#xD;
      group will receive empagliflozin 10 mg 1 month before planned percutaneous coronary&#xD;
      interventions and for 12 months thereafter in addition to previously taken hypoglycemic&#xD;
      therapy. Patients of the second group will continue to take previously prescribed&#xD;
      hypoglycemic therapy.&#xD;
&#xD;
      Thus, the safety and effectiveness of empagliflozin for preoperative preparation of patients&#xD;
      with type 2 diabetes before planned percutaneous coronary interventions will be evaluated, as&#xD;
      well as the impact on the immediate and long-term outcomes of percutaneous coronary&#xD;
      interventions in comparison with patients on standard hypoglycemic therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glomerular filtration rate(GFR)</measure>
    <time_frame>baseline-24 weeks</time_frame>
    <description>The glomerular filtration rate(GFR) will be measured at each visit. GFR more than 60 will be recognized as normal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1C level</measure>
    <time_frame>baseline-24 weeks</time_frame>
    <description>The HbA1C will be measured (in %) at each visit. HbA1C less than 6.1% will be recognized as normal.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment group are patients with stable coronary artery disease before planned percutaneous coronary intervention. All of them will receive empagliflozin additionally to previously taken hypoglycemic treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients continue previously prescribed medication intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10Mg Tab</intervention_name>
    <description>Patients from treatment group received empagliflozin 10 mg daily additionally to previously prescribed diabetes medication</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>metformin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hypoglycemic therapy</intervention_name>
    <description>hypoglycemic therapy.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>metformin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed inform concent&#xD;
&#xD;
          -  stable coronary artery disease&#xD;
&#xD;
          -  planned percutaneous coronary intervention&#xD;
&#xD;
          -  diabetes mellitus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previously performed coronary revascularization&#xD;
&#xD;
          -  glomerular filtration rate less than 45 ml/min&#xD;
&#xD;
          -  intolerance to empagliflozin&#xD;
&#xD;
          -  serum potassium more than 5/5 mmol/l&#xD;
&#xD;
          -  heart failure (NYHA III-IV)&#xD;
&#xD;
          -  congenital heart disease&#xD;
&#xD;
          -  acute coronary syndrome less than 3 months before enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Barbarash</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute for complex issues of cardiovascular diseases</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Research Institute for Complex Problems of Cardiovascular Diseases, Russia</investigator_affiliation>
    <investigator_full_name>Olga Barbarash</investigator_full_name>
    <investigator_title>Principal</investigator_title>
  </responsible_party>
  <keyword>stable coronary artery disease</keyword>
  <keyword>empagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

